image of employee and book

Our strategy

Image of typing on laptop

Our approach

British Patient Capital invests in a diversified portfolio of best-in-class venture and growth capital funds, capturing value through financing the growth of innovative companies. We invest on a commercial basis to deliver competitive returns and manage risk.

We manage a £2.5bn investment programme designed to unlock an additional £5bn of institutional capital to support UK businesses with high growth potential to access the long-term financing they need to scale up.

As well as providing our own funding we work to encourage more investors to make allocations to this asset class by demonstrating that a long-term patient capital investment strategy can produce commercially attractive returns.

Once we’ve established a strong record, and have proved the value of the asset class, we intend to privatise British Patient Capital at an appropriate time in the future.

Image of face masks

The impact of Covid-19

As we adapt to the impact of Covid-19, breakthrough innovations based on digitisation, deep technology and life sciences are set to create a wave of transformative, high-growth companies.

With many world-class universities, a strong track record in science and research, and a technology sector now regularly producing global champions, the UK is well positioned to be a leader of this wave.

With £1.5bn* still be to be deployed, it’s the long-term patient capital that we, and others provide, that will fuel innovation, and power economic growth.

*As at 31 March 2020